Lv1
70 积分 2025-03-18 加入
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
21天前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
22天前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
22天前
已完结
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
1个月前
已完结
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
3个月前
已完结
Impact of Sinus CT Severity Score on the Outcomes of Endoscopic Sinus Surgery in Eosinophilic CRSwNP
3个月前
已完结
MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed
3个月前
已完结
EP.12D.04 Treatment Pattern and Clinical Outcome in Chinese NSCLC Patients with MET Alterationwho Had Disease Progressionon EGFR-TKIs
3个月前
已完结
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
3个月前
已完结
皖公网安备34019202002308
